Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9331689 | 0.90 | MAOA (0.50) | MAOAKDM1AMAOBHTR2CHTR2B | |
| SCHEMBL4264590 | 0.82 | KDM1A (0.44) | KDM1AMMP1MMP9NISCH | |
| SCHEMBL4168557 | 0.74 | KDM4E (0.38) | MAOAHTR2CHTR2BHTR2AALDH1A1 | |
| SCHEMBL4968647 | 0.74 | KDM4E (0.38) | MAOAHTR2CHTR2BHTR2AALDH1A1 | |
| SCHEMBL10518245 | 0.74 | MAOA (0.54) | MAOAMAOB | |
| SCHEMBL2145393 | 0.73 | HTR2A (0.55) | MAOAHTR2CHTR2A | |
| SCHEMBL28301764 | 0.73 | HTR2A (0.55) | MAOAHTR2CHTR2A | |
| SCHEMBL9158101 | 0.73 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL2218295 | 0.73 | HTR2C (0.54) | KDM1AHTR2CHTR2BNISCHHTR2A | |
| SCHEMBL16874793 | 0.72 | CYP2D6 (0.53) | MAOAHTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | MAOA 1193/4885KDM1A 2737/4885MAOB 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.